CpG寡核苷酸作为针对传染病和癌症的疫苗佐剂的临床评估。
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.
作者信息
Scheiermann Julia, Klinman Dennis M
机构信息
Cancer and Inflammation Program, National Cancer Institute, NIH, Frederick MD 21702, United States.
Cancer and Inflammation Program, National Cancer Institute, NIH, Frederick MD 21702, United States.
出版信息
Vaccine. 2014 Nov 12;32(48):6377-89. doi: 10.1016/j.vaccine.2014.06.065. Epub 2014 Jun 24.
Abstract
Synthetic oligonucleotides (ODN) that express unmethylated "CpG motifs" trigger cells that express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells. CpG ODN induce an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. Their utility as vaccine adjuvants was evaluated in a number of clinical trials. Results indicate that CpG ODN improve antigen presentation and the generation of vaccine-specific cellular and humoral responses. This work provides an up-to-date overview of the utility of CpG ODN as adjuvants for vaccines targeting infectious agents and cancer.
摘要
表达未甲基化“CpG基序”的合成寡核苷酸（ODN）可激活表达Toll样受体9的细胞。在人类中，这包括浆细胞样树突状细胞和B细胞。CpG ODN可诱导以Th1和促炎细胞因子产生为特征的先天免疫反应。在多项临床试验中评估了它们作为疫苗佐剂的效用。结果表明，CpG ODN可改善抗原呈递以及疫苗特异性细胞和体液反应的产生。这项工作提供了关于CpG ODN作为针对传染病原体和癌症的疫苗佐剂效用的最新概述。
相似文献
1
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.CpG寡核苷酸作为针对传染病和癌症的疫苗佐剂的临床评估。
Vaccine. 2014 Nov 12;32(48):6377-89. doi: 10.1016/j.vaccine.2014.06.065. Epub 2014 Jun 24.
2
Adjuvant properties of CpG oligonucleotides in primates.CpG寡核苷酸在灵长类动物中的佐剂特性。
Methods Mol Med. 2006;127:139-58. doi: 10.1385/1-59745-168-1:139.
3
CpG DNA as a vaccine adjuvant.CpG DNA 作为疫苗佐剂。
Expert Rev Vaccines. 2011 Apr;10(4):499-511. doi: 10.1586/erv.10.174.
4
CpG Oligonucleotides as Vaccine Adjuvants.CpG 寡核苷酸作为疫苗佐剂。
Methods Mol Biol. 2021;2197:51-85. doi: 10.1007/978-1-0716-0872-2_4.
5
Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.免疫刺激性 CpG 寡核苷酸：对基因表达的影响及其作为疫苗佐剂的应用。
Vaccine. 2010 Feb 23;28(8):1919-23. doi: 10.1016/j.vaccine.2009.10.094.
6
Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.脂质修饰的CpG寡核苷酸的免疫刺激特性
Mol Pharm. 2017 Aug 7;14(8):2815-2823. doi: 10.1021/acs.molpharmaceut.7b00335. Epub 2017 Jul 24.
7
Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.通过阳离子明胶纳米颗粒递送可显著增强CpG寡核苷酸的免疫刺激作用。
Pharm Res. 2008 Mar;25(3):551-62. doi: 10.1007/s11095-007-9410-5. Epub 2007 Oct 3.
8
CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.CpG寡核苷酸作为针对传染病疫苗的佐剂。
Adv Drug Deliv Rev. 2009 Mar 28;61(3):248-55. doi: 10.1016/j.addr.2008.12.012. Epub 2009 Jan 14.
9
10
DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.DAMP 诱导佐剂和 PAMP 佐剂并行增强流感裂解疫苗接种的保护性 2 型和 1 型免疫应答。
Front Immunol. 2018 Nov 20;9:2619. doi: 10.3389/fimmu.2018.02619. eCollection 2018.
引用本文的文献
1
Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments.癌症免疫治疗中的肠道菌群失调：微生物群介导的耐药性及新出现的治疗方法
Front Immunol. 2025 Aug 25;16:1575452. doi: 10.3389/fimmu.2025.1575452. eCollection 2025.
2
Adjuvantation of Kyasanur Forest Disease vaccine with TLR9 agonist CpG adjuvant enhances immunological efficacy and potency of the vaccine.用Toll样受体9（TLR9）激动剂CpG佐剂辅助卡亚桑努尔森林病疫苗可增强该疫苗的免疫效力和效能。
PLoS One. 2025 Jul 31;20(7):e0329348. doi: 10.1371/journal.pone.0329348. eCollection 2025.
3
Advances in vaccine adjuvant development and future perspectives.疫苗佐剂研发进展与未来展望
Drug Deliv. 2025 Dec;32(1):2517137. doi: 10.1080/10717544.2025.2517137. Epub 2025 Jun 19.
4
Dual prophylactic and therapeutic potential of iPSC-based vaccines and neoantigen discovery in colorectal cancer.基于诱导多能干细胞的疫苗在结直肠癌中的双重预防和治疗潜力及新抗原发现
Theranostics. 2025 Apr 28;15(12):5890-5908. doi: 10.7150/thno.111400. eCollection 2025.
5
Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction.利用白蛋白-CpG寡核苷酸共价偶联物的FcRn结合作用实现有效的TLR9免疫诱导。
J Biol Chem. 2025 Apr 11;301(6):108508. doi: 10.1016/j.jbc.2025.108508.
6
Combination adjuvant improves influenza virus immunity by downregulation of immune homeostasis genes in lymphocytes.联合佐剂通过下调淋巴细胞中免疫稳态基因来提高流感病毒免疫力。
Immunohorizons. 2025 Jan 24;9(2). doi: 10.1093/immhor/vlae007.
7
Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults.关于含或不含CpG ODN佐剂的Na-GST-1/氢氧化铝钩虫疫苗在未感染钩虫的成年人中的安全性和免疫原性的随机、观察者盲法、对照1期研究。
PLoS Negl Trop Dis. 2024 Dec 30;18(12):e0012788. doi: 10.1371/journal.pntd.0012788. eCollection 2024 Dec.
8
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response.接种疫苗系列完成后一个月时抗原特异性 T 细胞免疫的程度可预测抗肿瘤免疫反应的长期持续。
J Immunother Cancer. 2024 Nov 9;12(11):e010251. doi: 10.1136/jitc-2024-010251.
9
Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma.用于胶质母细胞瘤基因治疗快速转化的反义寡核苷酸
Cancers (Basel). 2024 May 20;16(10):1944. doi: 10.3390/cancers16101944.
10
Efficacy and regulatory strategies of gut microbiota in immunotherapy: a narrative review.肠道微生物群在免疫治疗中的功效及调控策略：一篇叙述性综述
Transl Cancer Res. 2024 Apr 30;13(4):2043-2063. doi: 10.21037/tcr-24-316. Epub 2024 Apr 15.
本文引用的文献
1
Recent progress concerning CpG DNA and its use as a vaccine adjuvant.关于 CpG DNA 及其作为疫苗佐剂的最新进展。
Expert Rev Vaccines. 2014 Feb;13(2):299-312. doi: 10.1586/14760584.2014.863715. Epub 2013 Nov 26.
2
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.Ipilimumab 3mg/kg 在预处理、转移性、黏膜黑色素瘤患者中的疗效和安全性。
Eur J Cancer. 2014 Jan;50(1):121-7. doi: 10.1016/j.ejca.2013.09.007. Epub 2013 Oct 4.
3
Recombinant cancer vaccines and new vaccine targets. Interview by Jenaid Rees.重组癌症疫苗和新的疫苗靶点。采访：Jenaid Rees。
Expert Rev Vaccines. 2013 Oct;12(10):1121-4. doi: 10.1586/14760584.2013.836913. Epub 2013 Oct 7.
4
Trial Watch: Toll-like receptor agonists for cancer therapy.试验观察：用于癌症治疗的 Toll 样受体激动剂
Oncoimmunology. 2013 Aug 1;2(8):e25238. doi: 10.4161/onci.25238. Epub 2013 Jun 10.
5
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.辅助 MAGE-A3 免疫疗法治疗切除的非小细胞肺癌：II 期随机研究结果。
J Clin Oncol. 2013 Jul 1;31(19):2396-403. doi: 10.1200/JCO.2012.43.7103. Epub 2013 May 28.
6
Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.随机、双盲、安慰剂对照、含吸附型炭疽疫苗和 CPG 7909（AV7909）的 4 种制剂在健康成年志愿者中的安全性和免疫原性研究。
Vaccine. 2013 Jun 26;31(30):3051-8. doi: 10.1016/j.vaccine.2013.04.063. Epub 2013 May 10.
7
Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.激动 Toll 样受体 9 可减少病毒学抑制的 HIV 感染者的前病毒储存库。
PLoS One. 2013 Apr 26;8(4):e62074. doi: 10.1371/journal.pone.0062074. Print 2013.
8
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.一项关于免疫刺激性 CpG 7909 寡脱氧核苷酸和 90 钇替伊莫单抗替伊肟替西单抗放射性免疫治疗复发 B 细胞非霍奇金淋巴瘤的 I 期临床试验。
Am J Hematol. 2013 Jul;88(7):589-93. doi: 10.1002/ajh.23460. Epub 2013 Jun 12.
9
Anthrax: an update.炭疽病：最新情况
Asian Pac J Trop Biomed. 2011 Dec;1(6):496-501. doi: 10.1016/S2221-1691(11)60109-3.
10
Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.用 CpG-DNA-脂质体复合物配制的血凝素衍生合成肽免疫可诱导小鼠抵抗致死性流感病毒感染的保护作用。
PLoS One. 2012;7(11):e48750. doi: 10.1371/journal.pone.0048750. Epub 2012 Nov 7.
Zotero 插件